Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Authors: Ursula A. Matulonis, Gerburg M. Wulf, William T. Barry, Michael J. Birrer, Shannon N. Westin, Sarah Farooq, K.M. Bell-McGuinn, Elizabeth Obermayer, C. Whalen, Tatum Spagnoletti, Wenjie Luo, H. Liu, Rosanna Hok, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, J. Liu, Lewis C. Cantley, EP Winer - Annals of Oncology 2016 cited by 220